S&P 500   3,006.72 (+0.69%)
DOW   26,827.64 (+0.21%)
QQQ   193.39 (+0.89%)
AAPL   240.51 (+1.73%)
FB   189.75 (+2.10%)
MSFT   138.39 (+0.71%)
GOOGL   1,244.23 (-0.01%)
AMZN   1,785.67 (+1.60%)
CGC   20.35 (+0.69%)
NVDA   196.11 (+2.95%)
MU   45.25 (+4.09%)
BABA   173.52 (+2.60%)
GE   8.79 (-1.90%)
TSLA   253.46 (-1.36%)
AMD   32.07 (+3.52%)
T   38.23 (-0.62%)
F   9.03 (-2.80%)
ACB   3.69 (+0.27%)
PRI   125.69 (+1.75%)
NFLX   278.05 (+1.00%)
BAC   31.02 (+2.21%)
GILD   65.22 (+0.48%)
DIS   130.26 (-0.48%)
S&P 500   3,006.72 (+0.69%)
DOW   26,827.64 (+0.21%)
QQQ   193.39 (+0.89%)
AAPL   240.51 (+1.73%)
FB   189.75 (+2.10%)
MSFT   138.39 (+0.71%)
GOOGL   1,244.23 (-0.01%)
AMZN   1,785.67 (+1.60%)
CGC   20.35 (+0.69%)
NVDA   196.11 (+2.95%)
MU   45.25 (+4.09%)
BABA   173.52 (+2.60%)
GE   8.79 (-1.90%)
TSLA   253.46 (-1.36%)
AMD   32.07 (+3.52%)
T   38.23 (-0.62%)
F   9.03 (-2.80%)
ACB   3.69 (+0.27%)
PRI   125.69 (+1.75%)
NFLX   278.05 (+1.00%)
BAC   31.02 (+2.21%)
GILD   65.22 (+0.48%)
DIS   130.26 (-0.48%)
Log in

Revive Therapeutics Stock Price, News & Analysis (CVE:RVV)

Today's Range N/A
50-Day Range
C$0.05
MA: C$0.06
C$0.07
52-Week Range N/A
Volume32,500 shs
Average Volume93,085 shs
Market CapitalizationC$3.62 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Revive Therapeutics Ltd. develops and commercializes cannabinoid-based products in Canada. The company develops REV-002, a bucillamine that has completed Phase II-A clinical studies for the treatment of acute gout flares. Its product pipeline also includes REV-004, a bucillamine for the treatment of cystinurial. The company has a research and development supply and collaboration agreement with WeedMD Inc. Revive Therapeutics Ltd. was incorporated in 2012 and is headquartered in Vaughan, Canada.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-905-6055535

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book ValueC$0.02 per share

Profitability

Miscellaneous

EmployeesN/A
Market CapC$3.62 million
Next Earnings Date11/27/2019 (Estimated)
OptionableNot Optionable

Receive RVV News and Ratings via Email

Sign-up to receive the latest news and ratings for RVV and its competitors with MarketBeat's FREE daily newsletter.


Revive Therapeutics (CVE:RVV) Frequently Asked Questions

What is Revive Therapeutics' stock symbol?

Revive Therapeutics trades on the Canadian Venture Exchange (CVE) under the ticker symbol "RVV."

When is Revive Therapeutics' next earnings date?

Revive Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, November 27th 2019. View Earnings Estimates for Revive Therapeutics.

Has Revive Therapeutics been receiving favorable news coverage?

News coverage about RVV stock has trended somewhat positive recently, according to InfoTrie. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Revive Therapeutics earned a daily sentiment score of 0.8 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Revive Therapeutics.

Who are some of Revive Therapeutics' key competitors?

What other stocks do shareholders of Revive Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Revive Therapeutics investors own include 1933 Industries (TGIF), Okta (OKTA), MOL Global (MOLGY), Aurora Cannabis (ACB), Canopy Growth (WEED), ICC Labs (ICC), iAnthus Capital (IAN), Hempco Food and Fiber (HEMP), Supreme Cannabis (FIRE) and Emblem (EMC).

Who are Revive Therapeutics' key executives?

Revive Therapeutics' management team includes the folowing people:
  • Mr. Craig Leon, Chairman & CEO (Age 51)
  • Mr. Fabio Chianelli, Pres & Director (Age 41)
  • Mr. Carmelo Marrelli C.A., C.P.A., CPA, B.Comm., CA, CGA, ACIS, Chief Financial Officer (Age 48)

How do I buy shares of Revive Therapeutics?

Shares of RVV and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

How big of a company is Revive Therapeutics?

Revive Therapeutics has a market capitalization of C$0.00. View Additional Information About Revive Therapeutics.

What is Revive Therapeutics' official website?

The official website for Revive Therapeutics is http://www.revivethera.com/.

How can I contact Revive Therapeutics?

Revive Therapeutics' mailing address is 5 Director Crt Suite 105, WOODBRIDGE, ON L4L 4S5, Canada. The company can be reached via phone at +1-905-6055535.


MarketBeat Community Rating for Revive Therapeutics (CVE RVV)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  50 (Vote Outperform)
Underperform Votes:  54 (Vote Underperform)
Total Votes:  104
MarketBeat's community ratings are surveys of what our community members think about Revive Therapeutics and other stocks. Vote "Outperform" if you believe RVV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RVV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel